Dihydroimidazophenanthridinium (DIP)-based DNA binding agents with tuneable structures and biological activity

ChemBioChem

Volumn 7, Issue 11, 2006, Pages 1757-1763

  Smith, Louise V ^a   Parenty, Alexis D C ^a   Guthrie, Kevin M ^a   Plumb, Jane ^a   Brown, Robert ^a   Cronin, Leroy ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Cytotoxicity; DNA binding agents; Drug design; Heterocyclic cations; Molecular modeling; Structure activity relationships

Indexed keywords

DIHYDROIMIDAZOPHENANTHRIDIUM; PHENANTHRIDINE DERIVATIVE; TETRAZOLIUM; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL STRUCTURE; CYTOTOXICITY; DNA BINDING; MICROTITER PLATE ASSAY; MOLECULAR MODEL; PRIORITY JOURNAL; VISCOSITY;

CELL LINE, TUMOR; CELL PROLIFERATION; DNA; HUMANS; HYDROPHOBICITY; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PHENANTHRIDINES;

EID: 33750993069     PISSN: 14394227     EISSN: 14397633     Source Type: Journal    
DOI: 10.1002/cbic.200600205     Document Type: Article

References (42)

1. A. R. Katritzky, C. W. Rees, Comprehensive Heterocyclic Chemistry, (Eds.: C. W. Bird, G. W. H. Cheeseman), Pergamon, New York, 1984, pp. 1-38.
2. A. D. C. Parenty, L. Cronin, UK Patent Application No. 0327524.5, 2003.
3. M. F. Brana, M. Cacho, A. Gradillas, B. de Pascual-Teresa, A. Ramos, Curr. Pharm. Des. 2001, 7, 1745-1780.
4. G. Wickham, A. S. Prakash, L. P. G. Wakelin, W. D. McFadyen, Biochem. Biophys. Acta 1991, 1073, 528-537.
5. M. A. Lynch, O. Duval, A. Sukhanova, J. Devy, S. P. Mackay, R. D. Waigh, Bioorg. Med. Chem. Lett. 2001, 11, 2643-2646.
6. J. Whittaker, W. D. McFadyen, B. C. Baguley, V. Murray, Anti-Cancer Drug Des. 2001, 16, 81-89;
7. J. Whittaker, W. D. McFadyen, G. Wickham, L. P. Wakelin, V. Murray, Nucleic Acids Res. 1998, 26, 3933-3939.
8. T. Phillips, I. Haw, A. J. H. M. Meijer, H. Adams, I. Soutar, L. Swanson, M. J. Sykes, J. A. Thomas, Biochemistry 2004, 43, 13657;
9. S. T. Mullins, P. G. Sammes, R. M. West, G. Yahioglu, J. Chem. Soc. Perkin Trans. 1 1996, 75-81.
10. D. T. A. Youssef, A. A. Khalifa, Pharmazie 2001, 56, 818-822.
11. T. Nakanishi, M. Suzuki, A. Saimoto, T. Kabasawa, J. Nat. Prod. 1999, 62, 864-867.
12. V. N. Buyanov, E. P. Baberkina, M. E. Samoilova, R. N. Akhvlediani, E. P. Frolova, Pharm. Chem. J. 1994, 28, 11-16.
13. L. M. Stark, X. F. Lin, A. L. Flippin, J. Org. Chem. 2000, 65, 3227-3230.
14. A. D. C. Parenty, L. V. Smith, A. L. Pickering, D-L. Long, L. Cronin, J. Org. Chem. 2004, 69, 5934-5946.
15. A. D. C. Parenty, L. V. Smith, K. M. Guthrie, J. Plumb, R. Brown, L. Cronin, J. Med. Chem. 2005, 48, 4504-4506.
16. R. Martínez, L. Chacón-García, Curr. Med. Chem. 2005, 12, 127-151.
17. N. Saijo, T. Tamura, K. Nishio, Cancer Chemother. Pharmacol. 2003, 52, 97-101.
18. K. M. Guthrie, A. D. C. Parenty, L. V. Smith, L. Cronin, A. Cooper, Biophys. Chem. 2006, in press.
19. 7), which is probably due to a more efficient hydrophobic binding mode in the duplex not requiring access to the minor groove thereby allowing the R group to twist into the DNA duplex.
20. It is possible to introduce LDAO detergent (lauryl dimethylamine oxide) to aid solubility, and to measure the binding constants for compounds like 10, but it was extremely difficult to obtain reproducible results.
21. D. Suh, J. B. Chaires, Bioorg. Med. Chem. 1995, 3, 723-728.
22. V. A. Bloomfield, D. M. Crothers, J. I. Tinoco, Physical Chemistry of Nucleic Acids, Harper and Row, New York, 1974, pp. 373-474.
23. H. P. Lu, L. M. Iakoucheva, E. S. Ackerman, J. Am. Chem. Soc. 2001, 123, 9184-9185.
24. J. A. Plumb, R. Milroy, S. B. Kaye, Cancer Res. 1989, 49, 4435-4440.
25. T. K. Ti, E. Bathory, E. J. Lavoie, A. R. Srinivasan, W. K. Olson, R. R. Sauers, L. F. Liu, D. S. Pilch, Biochemistry 2000, 39, 7107-7116.
26. D. E. Thurston, S. G. Lobo, The Chemotherapy of Cancer Vol. 42: Introduction to the Principle of Drug Design and Action, (Ed.: J. Smith) Harwood Academic, Amsterdam, 1998, pp. 11 751-11 761.
27. The "energies" calculated from the modelling studies are not directly comparable to the experimentally determined values for numerous reasons, however these numbers are best viewed as an arbitrary measure of the goodness of the fit of the structural models.
28. A. M. Angeles-Boza, P. M. Bradley, P. K. L. Fu, S. E. Wicke, J. Basca, K. R. Dunbar, C. Turro, Inorg. Chem. 2004, 43, 8510-8519.
29. W. A. Denny, B. C. Baguley, Curr. Top. Med. Chem. 2003, 3, 339-353.
30. W. A. Denny, Cancer Chemotherapeutic Agents (Ed.: W. O. Foye), American Chemical Society, 1995, pp. 218-239.
31. W. A. Denny, J. Med. Chem. 1986, 29, 1769.
32. Lipophilicity values (log P; partition coefficient for n-octanol/water) were estimated by using standard methods; see P. Buchwald, Perspect. Drug Discovery Des. 2000, 19, 19-45.
33. D. L. Yudilevich, Cell Membrane Transport: Experimental Approaches and Methodologies, Plenum, New York, 1991.
34. K. Saar, M. Lindgren, M. Hansen, E. Eiriksdottir, Y. Jiang, K. Rosenthal-Aizman, M. Sassian, U. Langel, Anal. Biochem. 2005, 345, 55-65.
35. J. B. Chaires, ACS Symp. Ser. 1995, 574, 156-167.
36. S. A. Shaikh, S. R. Ahmed, B. Jayaram, Arch. Biochem. Biophys. 2004, 429, 81-99.
37. T. Wiseman, S. Williston, J. F. Brandts, L-N. Lin, Anal. Biochem. 1989, 179, 131-137.
38. "Isothermal Titration Microcalorimetry", A. Cooper, C. M. Johnson in Microscopy, Optical Spectroscopy, and Macroscopic Techniques (Eds.: C. Jones, B. Mulloy, A. H. Thomas), Humana, Totowa, 1994, pp. 137-150.
39. G. Strathdee, M. J. MacKean, M. Illand, R. Brown, Oncogene 1999, 18, 2335-2341.
40. HyperCube, in HYPERCHEM, Release 7.5 for Windows, 2002.
41. T. M. Jones-Wilson, K. A. Deal, C. J. Anderson, D. W. McCarthy, Z. Kovacs, R. J. Motekaitis, A. D. Sherry, A. E. Martell and M. J. Welch, Nucl. Med. Biol. 1998, 25, 523.
42. G. Viola, F. Dall'Acqua, N. Gabellini, S. Moro, D. Vedaldi, H. Ihmels, ChemBioChem 2002, 3, 550-558.